|
28.02.2005 13:31:00
|
StemCells, Inc. Names Alan Jacobs Chief Medical Officer and Vice Presi
StemCells, Inc. Names Alan Jacobs Chief Medical Officer and Vice President of Clinical Research, Neural Program Jacobs Brings Expertise in Managing and Implementing Clinical Trials Involving Cell-Based Therapies for Neurological Disorders
StemCells, Inc. (NASDAQ: STEM) today announced that Dr. Alan Jacobs will join the company as chief medical officer and vice president of clinical research, neural program. Formerly the senior director of clinical development at Titan Pharmaceuticals, Jacobs offers valuable experience in managing clinical trial development of cell-based therapies for indications such as Parkinson's disease and stroke. In his current capacity, Jacobs will lead the company's adult human neural (brain) stem cell (HuCNS-SC) program through the clinical development process.
"Alan has expertly directed two separate cell-based therapies through late-stage clinical trials, and has worked with the leading neuroscience companies in the world including Titan and Elan," said Martin McGlynn, chief executive officer of StemCells, Inc. "For these reasons in particular, Alan will be an invaluable addition to StemCells, Inc. and will no doubt strengthen our scientific management team."
At Titan Pharmaceuticals, Jacobs led Titan's Central Nervous System (CNS) clinical development efforts which included Spheramine(R), a cell-based therapeutic for Parkinson's disease developed in collaboration with Schering AG. He designed and implemented phase II and III clinical studies, managed an ongoing multi-center trial and closely interacted with the Food and Drug Administration (FDA). Jacobs previously served as medical director of Layton Biosciences, where he was responsible for clinical and regulatory development of a neural cell line for the indications of stroke and Parkinson's disease. Jacobs has also worked with neuroscience company Elan Pharmaceuticals as assistant director of clinical affairs.
"I am excited to put my experience in neurological research to work for StemCells, Inc., and to leverage its impressive preclinical research supporting the safety and efficacy of neural stem cell treatments," said Jacobs. "I am committed to collaborating with the full scientific team to reach StemCells' ultimate objective--bringing neural stem cell therapies to the clinic and providing treatments for patients who currently have few viable medical options."
Jacobs brings a strong scientific and medical background in neuroscience. He has co-authored peer-reviewed research and review articles in prestigious journals such as Journal of Neuroscience, Neurosurgery, Experimental Neurology and Brain Research. He has also served as an expert resource for the National Institutes of Health NINDS Stroke Progress Review Group and Health Technology Center's Expert Panel on Stem Cell Technology, both in 2001. He currently is a member of the American Society of Experimental Neurotherapeutics and the American Society of Neurotransplantation and Repair.
Jacobs received a Ph.D from the University of Pennsylvania, David Mahoney Institute of Neuroscience, and an M.D. from the University of Pennsylvania, School of Medicine, in 1995. Following completion of these programs, Jacobs served as a resident neurosurgeon at the University of California, San Francisco Medical Center. He also received an M.S. in Electrical Engineering from Stanford University in 1988.
About StemCells, Inc.
StemCells, Inc. is a development stage biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. StemCells is the first company to directly identify and isolate human neural stem cells from normal brain tissue. These stem cells are expandable into cell banks for therapeutic use, which demonstrates the feasibility of using normal, non-genetically modified cells as cell-based therapies. StemCells is the only publicly traded company solely focused on stem cell research and development and has more than 40 U.S. and 100 non-U.S. patents, as well as 100 patent applications pending worldwide. Further information about the Company is available on its web site at: www.stemcellsinc.com.
Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. ("the Company"). The forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in the forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company's ability to obtain the capital resources needed to continue its current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; the uncertainty whether the FDA will approve the IND and permit the Company to proceed to clinical testing; the uncertainty regarding the outcome of the Phase I clinical trial and any other trials the Company may conduct in the future; the uncertainty regarding the validity and enforceability of issued patents; the uncertainty whether any products that may be generated in the Company's stem cell programs will prove clinically effective and not cause tumors or other side effects; the uncertainty whether the Company will achieve revenues from product sales or become profitable; uncertainties regarding the Company's obligations in regard to its former encapsulated cell therapy facilities in Rhode Island; and other factors that are described in Exhibit 99 to the Company's Annual Report on Form 10-K titled "Cautionary Factors Relevant to Forward-Looking Statements."
--30--JO/bo*
Business Editors/Health Editors
PALO ALTO, Calif.--(BUSINESS WIRE)--Feb. 28, 2005--
StemCells, Inc. (NASDAQ: STEM) today announced that Dr. Alan Jacobs will join the company as chief medical officer and vice president of clinical research, neural program. Formerly the senior director of clinical development at Titan Pharmaceuticals, Jacobs offers valuable experience in managing clinical trial development of cell-based therapies for indications such as Parkinson's disease and stroke. In his current capacity, Jacobs will lead the company's adult human neural (brain) stem cell (HuCNS-SC) program through the clinical development process.
"Alan has expertly directed two separate cell-based therapies through late-stage clinical trials, and has worked with the leading neuroscience companies in the world including Titan and Elan," said Martin McGlynn, chief executive officer of StemCells, Inc. "For these reasons in particular, Alan will be an invaluable addition to StemCells, Inc. and will no doubt strengthen our scientific management team."
At Titan Pharmaceuticals, Jacobs led Titan's Central Nervous System (CNS) clinical development efforts which included Spheramine(R), a cell-based therapeutic for Parkinson's disease developed in collaboration with Schering AG. He designed and implemented phase II and III clinical studies, managed an ongoing multi-center trial and closely interacted with the Food and Drug Administration (FDA). Jacobs previously served as medical director of Layton Biosciences, where he was responsible for clinical and regulatory development of a neural cell line for the indications of stroke and Parkinson's disease. Jacobs has also worked with neuroscience company Elan Pharmaceuticals as assistant director of clinical affairs.
"I am excited to put my experience in neurological research to work for StemCells, Inc., and to leverage its impressive preclinical research supporting the safety and efficacy of neural stem cell treatments," said Jacobs. "I am committed to collaborating with the full scientific team to reach StemCells' ultimate objective--bringing neural stem cell therapies to the clinic and providing treatments for patients who currently have few viable medical options."
Jacobs brings a strong scientific and medical background in neuroscience. He has co-authored peer-reviewed research and review articles in prestigious journals such as Journal of Neuroscience, Neurosurgery, Experimental Neurology and Brain Research. He has also served as an expert resource for the National Institutes of Health NINDS Stroke Progress Review Group and Health Technology Center's Expert Panel on Stem Cell Technology, both in 2001. He currently is a member of the American Society of Experimental Neurotherapeutics and the American Society of Neurotransplantation and Repair.
Jacobs received a Ph.D from the University of Pennsylvania, David Mahoney Institute of Neuroscience, and an M.D. from the University of Pennsylvania, School of Medicine, in 1995. Following completion of these programs, Jacobs served as a resident neurosurgeon at the University of California, San Francisco Medical Center. He also received an M.S. in Electrical Engineering from Stanford University in 1988.
About StemCells, Inc.
StemCells, Inc. is a development stage biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. StemCells is the first company to directly identify and isolate human neural stem cells from normal brain tissue. These stem cells are expandable into cell banks for therapeutic use, which demonstrates the feasibility of using normal, non-genetically modified cells as cell-based therapies. StemCells is the only publicly traded company solely focused on stem cell research and development and has more than 40 U.S. and 100 non-U.S. patents, as well as 100 patent applications pending worldwide. Further information about the Company is available on its web site at: www.stemcellsinc.com.
Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. ("the Company"). The forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in the forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company's ability to obtain the capital resources needed to continue its current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; the uncertainty whether the FDA will approve the IND and permit the Company to proceed to clinical testing; the uncertainty regarding the outcome of the Phase I clinical trial and any other trials the Company may conduct in the future; the uncertainty regarding the validity and enforceability of issued patents; the uncertainty whether any products that may be generated in the Company's stem cell programs will prove clinically effective and not cause tumors or other side effects; the uncertainty whether the Company will achieve revenues from product sales or become profitable; uncertainties regarding the Company's obligations in regard to its former encapsulated cell therapy facilities in Rhode Island; and other factors that are described in Exhibit 99 to the Company's Annual Report on Form 10-K titled "Cautionary Factors Relevant to Forward-Looking Statements."
--30--JO/bo*
CONTACT: Company Contact: Stemcells, Inc. Judi Lum, 650-475-3100 or Media Contact: Schwartz Communications, Inc. 781-684-0770 or 415-512-0770 stemcells@schwartz-pr.com
KEYWORD: CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Stemcells, Inc.
Copyright Business Wire 2005
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu StemCells Inc.mehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu StemCells Inc.mehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.